AUMdb

Venrock Adviser, Llc

SEC-registered Private Fund Manager · Mid-sized ($1B–$10B) CRD 169288 · SEC file 801-79382 · New York, NY · open.spotify.com
☆ Save with Pro ADV data as of Apr 28, 2026
Regulatory AUM
$4.5B
Discretionary
$4.5B
Clients
7
Avg AUM / client
$642M
Accounts
7
Employees
11

AUM over time

$403M $4.5B
Jul 2014 Dec 2025

Annual snapshots from Form ADV filings · as of Apr 28, 2026

Investments (13F portfolio — 33 positions, $2,679,121,858)

13F period Mar 31, 2026
#IssuerClassValueShares% of 13F% of AUM
1 Apogee Therapeutics Inc COM $714,882,829 8,493,321 26.7% 15.9%
2 Erasca Inc COM $265,073,898 16,382,812 9.89% 5.9%
3 Oruka Therapeutics Inc COM $203,480,393 4,148,428 7.6% 4.53%
4 Spyre Therapeutics Inc COM NEW $185,893,997 3,685,448 6.94% 4.14%
5 Kalvista Pharmaceuticals Inc COM $130,331,383 6,474,485 4.86% 2.9%
6 Dianthus Therapeutics Inc COM $99,025,600 1,180,000 3.7% 2.2%
7 Damora Therapeutics Inc COM NEW $93,333,111 3,603,595 3.48% 2.08%
8 Ocular Therapeutix Inc COM $87,638,463 10,346,926 3.27% 1.95%
9 Cogent Biosciences Inc COM $76,980,000 2,000,000 2.87% 1.71%
10 Viridian Therapeutics Inc COM $75,945,788 3,882,709 2.83% 1.69%
11 Savara Inc COM $75,022,448 13,740,375 2.8% 1.67%
12 Enliven Therapeutics Inc COM $67,672,175 1,726,331 2.53% 1.51%
13 Oric Pharmaceuticals Inc COM $54,731,423 4,319,765 2.04% 1.22%
14 Vor Biopharma Inc COM NEW $54,264,267 3,041,719 2.03% 1.21%
15 Maze Therapeutics Inc COM $47,820,715 1,602,034 1.78% 1.06%
16 Cytomx Therapeutics Inc COM $46,915,983 9,982,124 1.75% 1.04%
17 Jade Biosciences Inc COM NEW $45,246,114 3,220,364 1.69% 1.01%
18 Dyne Therapeutics Inc COM $39,413,043 2,173,913 1.47% 0.88%
19 Crescent Biopharma Inc. COM $39,193,791 2,133,576 1.46% 0.87%
20 Zura Bio Ltd CLASS A ORD SHS $38,288,191 6,434,990 1.43% 0.85%
21 Relmada Therapeutics Inc COM $33,709,925 4,843,380 1.26% 0.75%
22 Engene Holdings Inc COM $32,493,329 4,771,414 1.21% 0.72%
23 Tenax Therapeutics Inc COM NEW $26,787,439 1,675,262 1.0% 0.6%
24 Adlai Nortye Ltd SPONSORED ADS $22,232,099 3,212,731 0.83% 0.49%
25 Century Therapeutics Inc COM $19,652,174 8,695,652 0.73% 0.44%

Top 25 of 33 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).

Who they serve

Client typeClientsAUM% of AUM
Pooled investment vehicles (non-investment companies) 7 $4.5B 100.0%

Private funds (8)

Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $2.9B combined gross assets

FundTypeDomicileGross assetsOwners
Venrock Healthcare Capital Partners Eg, L.P. Hedge Fund Delaware $1.5B 74
Venrock Opportunities Fund, L.P. Private Equity Fund Delaware $658M 87
Venrock Healthcare Capital Partners Iii, L.P. Private Equity Fund Delaware $574M 67
Vhcp Co Investment Holdings Iii, Llc master Private Equity Fund Delaware $58.9M 167
Venrock Healthcare Capital Partners Ii, L.P. Private Equity Fund Delaware $51.1M 41
Vhcp Co Investment Holdings Ii, Llc master Private Equity Fund Delaware $20.4M 235
Venrock Healthcare Capital Partners, L.P. Private Equity Fund Delaware $1.4M 42
Vhcp Co Investment Holdings, Llc master Private Equity Fund Delaware $333K 126

People (4)

NameRole / titleCredentialsWith firm sinceOwnership
Roberts, Bryan, Edward Member Jul 2007 (19y) ≈ 37.5% – 75% via Vr Management, Llc
Harris, Lisa, Denise Cfo Of Vr Adviser, Llc Mar 2014 (12y) Less than 5%
Koh, Bong, Young Manager Of Vr Adviser, Llc Jul 2016 (10y) ≈ 37.5% – 75% via Vr Management, Llc
Neu, Evan, Wolfe Cco And Clo Of Vr Adviser, Llc Jan 2023 (4y) Less than 5%

Entity owners (Schedule A/B)

EntityTitle / statusSinceSch.Ownership
Vr Management, Llc Member Of Vr Adviser, Llc Jul 2014 A 75% or more

Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.

Estimated effective ownership (look-through of filed bands):

  • Roberts, Bryan, Edward: 50% – 75% of Vr Management, Llc × 75% – 100% direct ≈ 37.5% – 75% of the firm
  • Koh, Bong, Young: 50% – 75% of Vr Management, Llc × 75% – 100% direct ≈ 37.5% – 75% of the firm

Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.

Private funds (8, $2.9B gross assets)

FundTypeGross assetsMin. investmentOwners
Venrock Healthcare Capital Partners Eg, L.P. Hedge Fund $1.5B $0 74
Venrock Opportunities Fund, L.P. Private Equity Fund $658M $0 87
Venrock Healthcare Capital Partners Iii, L.P. Private Equity Fund $574M $0 67
Vhcp Co Investment Holdings Iii, Llc Private Equity Fund $58.9M $0 167
Venrock Healthcare Capital Partners Ii, L.P. Private Equity Fund $51.1M $0 41
Vhcp Co Investment Holdings Ii, Llc Private Equity Fund $20.4M $0 235
Venrock Healthcare Capital Partners, L.P. Private Equity Fund $1.4M $0 42
Vhcp Co Investment Holdings, Llc Private Equity Fund $333K $0 126

From Form ADV Section 7.B private fund reporting.

Documents (1 archived)

FormPeriodSize
Form ADV (full filing) 04/28/2026 3.34 MB View · PDF · Source ↗

Archived copies of the firm's regulatory filings, versioned by content hash.

Disciplinary disclosures

No disciplinary events reported on the firm's latest Form ADV filing.

How they charge

  • • Percentage of assets under management
  • • Performance-based fees
  • • Other fees
  • • SEE MISCELLANEOUS NOTE IN SCHEDULE D

Services

  • • Portfolio management for pooled investment vehicles

Custody

Firm reports it does not have custody of client funds or securities (Item 9.A).

No custodian data reported or mined yet.

Source

All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Apr 28, 2026.

View current Form ADV (SEC/IAPD) ↗